Press Releases on November 1, 2017 - EIN Presswire - Press Release Distribution Service

Published on November 1, 2017 - 13:05 GMT

Actinium Pharmaceuticals Announces Multiple Posters/Abstracts Accepted for 59th Annual American Society of Hematology Meeting ...

Data from ongoing Actimab-A Phase 2 clinical trial highlighting efficacy, safety profile and clinical strategy as a single agent targeting CD33 in patients with AML Studies highlighting enhanced killing of multiple myeloma cells by Actinium labeled …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on November 1, 2017 - 13:05 GMT

HealthEquity’s Ashley Dreier Honored By The Women Tech Council For Technology Leadership

DRAPER, Utah, Nov. 01, 2017 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY), a leading health savings account (HSA) provider, is pleased to announce that its Chief Information and Technology Officer (CTO), Ashley Dreier, received the Technology …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on November 1, 2017 - 13:05 GMT

MacroGenics to Present Phase 1 Data on Flotetuzumab, a CD123 x CD3 DART® Molecule, at 59th Annual ASH Meeting

ROCKVILLE, MD, Nov. 01, 2017 (GLOBE NEWSWIRE) -- – MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as …

Distribution channels: Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry ...

Published on November 1, 2017 - 13:05 GMT

Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting

BERKELEY, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced preclinical data presentations relating to BION-1301, the company’s anti- …

Distribution channels: Conferences & Trade Fairs, Technology ...

Published on November 1, 2017 - 13:05 GMT

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of ...

NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company focused on developing treatments for rare and life-threatening diseases, today announced that Phase 1a/1b data on CAEL-101 for …

Distribution channels: Conferences & Trade Fairs, Technology ...

Published on November 1, 2017 - 13:03 GMT

Superior Uniform Group Declares Regular Quarterly Cash

SEMINOLE, Fla., Nov. 01, 2017 (GLOBE NEWSWIRE) -- The Board of Directors of Superior Uniform Group, Inc. (NASDAQ:SGC) today declared a quarterly dividend of $0.0950 per share, payable November 29, 2017, to shareholders of record November 15, 2017. About …

Distribution channels: Banking, Finance & Investment Industry, Retail ...

Published on November 1, 2017 - 13:03 GMT

nuyu™ Clothing Line Offers the Perfect Gift for College Women, Parents and Alumni just in Time for the Holiday Season

NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- In a few short weeks, college students will be rushing home for the holiday break to enjoy time with family, indulge in home-cooked meals and escape the college grind. To help make shopping for these undergrads a …

Distribution channels: Beauty & Hair Care, Retail ...

Published on November 1, 2017 - 13:03 GMT

Aclara Research Continues to Lead the Cannabis Industry with Release of Latest Study

CHICAGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aclara Research, a leader in the development of patient and consumer insights within the cannabis industry, today released the preliminary results of their latest study examining patient usage of medical cannabis …

Distribution channels: Banking, Finance & Investment Industry, Consumer Goods ...

Published on November 1, 2017 - 13:02 GMT

Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting

NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that SL-401, a novel targeted therapeutic …

Distribution channels: Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry ...

Published on November 1, 2017 - 13:02 GMT

Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ...

BERKELEY HEIGHTS, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response …

Distribution channels: Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry ...